-
公开(公告)号：US11708392B2
公开(公告)日：2023-07-25
申请号：US17012724
申请日：2020-09-04
Applicant: BIONIZ, LLC
Inventor： Yutaka Tagaya , Nazli Azimi
IPC: C07K7/08 , C07K7/06 , C07K14/52 , C07K14/54 , A61K8/64 , A61K38/20 , A61K38/10 , A61K38/00 , A61Q3/00 , A61Q7/00 , A61Q19/00 , A61Q19/08 , A61P1/04 , A61P3/10 , A61P5/14 , A61P11/00 , A61P11/02 , A61P11/06 , A61P11/08 , A61P17/00 , A61P17/02 , A61P17/06 , A61P17/10 , A61P17/14 , A61P19/02 , A61P25/00 , A61P25/02 , A61P25/28 , A61P27/02 , A61P27/16 , A61P29/00 , A61P35/02 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , A61K47/64
CPC classification number: C07K7/08 , A61K8/64 , A61K38/20 , A61K47/642 , A61K47/643 , A61Q3/00 , A61Q7/00 , A61Q19/00 , A61Q19/004 , A61Q19/08 , C07K7/06 , C07K14/52 , C07K14/54 , A61K38/00 , A61K38/10
Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
-
公开(公告)号：US09959384B2
公开(公告)日：2018-05-01
申请号：US15103804
申请日：2014-12-10
Applicant: BIONIZ, LLC
Inventor： Nazli Azimi , Yutaka Tagaya
IPC: A61K38/00 , A61K38/10 , A61K38/20 , A61K8/64 , C07K14/52 , C07K7/06 , C07K7/08 , G06F19/16 , C40B30/02 , G01N33/50 , G06F19/18
CPC classification number: G06F19/16 , C40B30/02 , G01N33/5041 , G01N2333/54 , G01N2333/5412 , G01N2333/5443 , G01N2333/7155 , G06F19/18
Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
-
3.发明申请公开(公告)号：US20160000877A1
公开(公告)日：2016-01-07
申请号：US14852240
申请日：2015-09-11
Applicant: Bioniz, LLC
Inventor： Yutaka Tagaya , Nazli Azimi
CPC classification number: C07K7/08 , A61K8/64 , A61K38/00 , A61K38/10 , A61K38/20 , A61K47/642 , A61K47/643 , A61Q3/00 , A61Q7/00 , A61Q19/00 , A61Q19/004 , A61Q19/08 , C07K7/06 , C07K14/52 , C07K14/54
Abstract: The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. The present embodiments relate to the design of peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. In several embodiments, peptide antagonists exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.
Abstract translation: （IL-4），白细胞介素-7（IL-7），白介素9（IL-9），白细胞介素-15（IL-15），白细胞介素 和白细胞介素-21（IL-21）与重要的人类疾病如白血病，自身免疫疾病，胶原病，糖尿病，皮肤病，退行性神经元疾病和移植物抗宿主病（GvHD）有关。 因此，γc-细胞因子活性的抑制剂是有价值的治疗和美容剂以及研究工具。 本实施方案涉及基于用于抑制γc-细胞因子活性的共有γc-亚基结合位点的肽拮抗剂的设计。 在几个实施方案中，肽拮抗剂显示出Simul-Block活性，抑制多种γc-细胞因子家族成员的活性。
-
公开(公告)号：US20230060637A1
公开(公告)日：2023-03-02
申请号：US17813304
申请日：2022-07-18
Applicant: Bioniz, LLC
Inventor： Nazli Azimi
IPC: A61K38/20 , C07K14/54 , A61Q7/00 , A61K8/64 , A61Q3/00 , A61Q19/00 , A61Q19/08 , A61P17/18 , A61P31/14 , A61P35/00 , C07K7/08 , C07K14/55 , C07K19/00
Abstract: Embodiments relate to peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting γc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.
-
公开(公告)号：US20210082537A1
公开(公告)日：2021-03-18
申请号：US17083099
申请日：2020-10-28
Applicant: BIONIZ, LLC
Inventor： Nazli Azimi , Yutaka Tagaya
Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
-
Patent Agency Ranking
公开(公告)号：US20190070263A1
公开(公告)日：2019-03-07
申请号：US15767133
申请日：2016-10-06
Applicant: Bioniz, LLC
Inventor： Nazli Azimi
IPC: A61K38/20 , C07K19/00 , C07K14/55 , A61Q19/00 , A61Q19/08 , A61P35/00 , C07K7/08 , A61Q3/00 , A61Q7/00 , C07K14/54 , A61P17/18 , A61P31/14
Abstract: Embodiments relate to peptide antagonists of -family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of -cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting yc-cytokine activity involve raising neutralizing antibodies against each individual -cytokine family member/′ receptor subunit. However, success has been limited and often multiple -cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus -subunit binding site to inhibit -cytokine activity. Such approach allows for flexibility in antagonist design. In several embodiments, peptides exhibit Simul-Block activity, inhibiting the activity of multiple -cytokine family members.
-
公开(公告)号：US20180237475A1
公开(公告)日：2018-08-23
申请号：US15957806
申请日：2018-04-19
Applicant: BIONIZ, LLC
Inventor： Yutaka Tagaya , Nazli Azimi
IPC: C07K7/08 , A61Q7/00 , A61K38/20 , C07K14/52 , A61Q19/00 , A61Q19/08 , A61Q3/00 , C07K7/06 , A61K47/64 , A61K8/64 , A61K38/10 , A61K38/00
Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
-
公开(公告)号：US20170240607A1
公开(公告)日：2017-08-24
申请号：US15585666
申请日：2017-05-03
Applicant: Bioniz, LLC
Inventor： Nazli Azimi
IPC: C07K14/54
CPC classification number: C07K14/54 , A61K8/64 , A61K38/00 , A61Q3/00 , A61Q7/00 , A61Q19/004 , A61Q19/08 , C07K14/5406 , C07K14/5418 , C07K14/5425 , C07K14/5443 , C07K2319/02 , C07K2319/30 , C07K2319/31
Abstract: Peptide antagonists of γc-family cytokines, which is associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (GvHD). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools. Traditional approaches to inhibiting γc-cytokine activity involve raising neutralizing antibodies against each individual γc-cytokine family member/receptor subunit. However, success has been limited and often multiple γc-cytokine family members co-operate to cause the disease state. Combinatorial use of neutralizing antibodies raised against each factor is impractical and poses an increased risk of adverse immune reactions. The present embodiments overcome these shortcomings by utilizing peptide antagonists based on the consensus γc-subunit binding site to inhibit γc-cytokine activity. Such approach allows for flexibility in antagonist design. The disclosed peptides exhibit Simul-Block activity, inhibiting the activity of multiple γc-cytokine family members.
-
公开(公告)号：US20230197187A1
公开(公告)日：2023-06-22
申请号：US17933028
申请日：2022-09-16
Applicant: BIONIZ, LLC
Inventor： Nazli Azimi , Yutaka Tagaya
CPC classification number: G16B15/00 , G16B20/00 , G16B35/00 , G16C20/60 , G16B35/20 , G16B20/50 , G16B20/30 , G01N33/5041 , G16B15/30
Abstract: Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.
-
10.发明申请公开(公告)号：US20200347128A1
公开(公告)日：2020-11-05
申请号：US16863914
申请日：2020-04-30
Applicant: BIONIZ, LLC
Inventor： Yutaka Tagaya , Nazli Azimi
Abstract: The γc-family cytokines, Interleukin-2 (IL-2), Interleukin-4 (IL-4), Interleukin-7 (IL-7), Interleukin-9 (IL-9), Interleukin-15 (IL-15), and Interleukin-21 (IL-21), are associated with important human diseases, such as alopecia and alopecia associated disorders. Compositions, methods, and kits to modulate signaling by at least one γc-cytokine family member for inhibiting, ameliorating, reducing a severity of, treating, delaying the onset of, or preventing at least one alopecia related disorder are described.
-
-
-
-
-
-
-
-
-
Search Results
29
records
(took 0.016 seconds)
